Lucinactant
Also known as: KL4 Peptide, Surfaxin
Lucinactant is a synthetic lung surfactant containing the KL4 peptide that mimics natural pulmonary surfactant function. This peptide reduces surface tension in the alveoli and prevents lung collapse in premature infants and patients with respiratory distress.
Lucinactant is a 2656.2 Da research peptide. Lucinactant is a synthetic lung surfactant containing the KL4 peptide that mimics natural pulmonary surfactant function. This peptide reduces surface tension in the alveoli and prevents lung collapse in premature infants and patients with respiratory distress.
Also called: KL4 Peptide, Surfaxin
2656.2
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
5.8-5.8
Typical Dose
ml/kg
Overview
Lucinactant represents a breakthrough in synthetic lung surfactant therapy, incorporating the KL4 peptide sequence that replicates the critical functions of surfactant protein B (SP-B). The peptide contains 21 amino acids with a specific lysine-leucine repeat pattern that enables proper membrane insertion and surface tension reduction. Unlike animal-derived surfactants, lucinactant eliminates the risk of viral transmission while providing consistent therapeutic effects. The KL4 peptide anchors into the lipid bilayer of alveolar surfaces, facilitating the spreading and stability of phospholipids essential for respiratory function. Research demonstrates that lucinactant enhances lung compliance, reduces ventilator requirements, and improves oxygenation in both neonatal and adult respiratory conditions. The synthetic nature allows for precise dosing and reduced immunogenic potential compared to bovine or porcine surfactant preparations.
Key Takeaways: Lucinactant
- Strongest evidence supports Lucinactant for respiratory distress syndrome treatment and improved lung compliance
- Research doses typically range from 5.8 to 5.8 ml/kg via intratracheal
- 3 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 6-12 hours (intratracheal)
- 4 cited research studies in this guide
Mechanism of Action
Lucinactant functions by inserting its KL4 peptide component into alveolar membrane surfaces, where it organizes phospholipids into stable monolayers. The peptide reduces surface tension from approximately 70 mN/m to near 0 mN/m during expiration, preventing alveolar collapse. KL4 enhances the adsorption and spreading of dipalmitoylphosphatidylcholine (DPPC), the primary surface-active component. The peptide also facilitates recycling of surfactant lipids and maintains membrane fluidity across varying lung volumes. This mechanism directly addresses surfactant deficiency in respiratory distress syndrome and acute lung injury.
Research Benefits
Lucinactant at a Glance
Lucinactant functions by inserting its KL4 peptide component into alveolar membrane surfaces, where it organizes phospholipids into stable monolayers.
Respiratory Distress Syndrome Treatment
Strong EvidenceReduces mortality and ventilator dependence in premature infants by restoring normal lung surfactant function and preventing alveolar collapse during expiration.
Improved Lung Compliance
Strong EvidenceIncreases lung elasticity and reduces the work of breathing by maintaining optimal surface tension in alveolar spaces, allowing for easier lung expansion.
Enhanced Oxygenation
Strong EvidenceImproves arterial oxygen levels and oxygen saturation by preventing ventilation-perfusion mismatches and maintaining stable alveolar recruitment.
Reduced Pneumothorax Risk
Moderate EvidenceDecreases the incidence of air leaks and pneumothorax by maintaining consistent alveolar stability and preventing overdistention from high ventilator pressures.
Bronchopulmonary Dysplasia Prevention
Moderate EvidenceMay reduce long-term lung damage and chronic lung disease by minimizing ventilator-induced lung injury and inflammation in premature infants.
Adult Respiratory Support
PreliminaryShows potential in treating acute respiratory distress syndrome (ARDS) and other adult lung conditions by supplementing deficient or dysfunctional surfactant.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Neonatal RDS treatment | 5.8–5.8 ml/kg | intratracheal |
| Adult ARDS research | 300–600 ml | intratracheal |
Frequency
Single dose or repeat every 6 hours as needed
Timing
As soon as possible after birth for RDS, or at diagnosis for other conditions
Cycle Length
Acute treatment only - discontinue when respiratory status stabilizes
Research Notes
- 1Must be administered through endotracheal tube under sterile conditions
- 2Warm to body temperature before administration
- 3Temporary ventilator disconnection may be required during instillation
- 4Monitor oxygen saturation and ventilator pressures closely during treatment
Reconstitution Guide
Standard Reconstitution
Vial Size
35 mg
Bacteriostatic Water
0 mL
Concentration
Infinity mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Lucinactant vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C refrigerated. 24 months unopened, use within 2 hours once opened.
Storage Temperature
2-8°C refrigerated
Shelf Life
24 months unopened, use within 2 hours once opened
Important Notes
- •Supplied as ready-to-use suspension - no reconstitution required
- •Gentle swirling may be needed to ensure uniform suspension
- •Do not shake vigorously as this may damage the peptide structure
- •Single use vial only - discard after one administration
Lucinactant Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Lucinactant Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Transient oxygen desaturation during administration
- !Bradycardia
- !Endotracheal tube blockage
- !Pulmonary hemorrhage
- !Hypotension
- !Reflux of surfactant into mouth
- !Increased secretions requiring suctioning
- !Transient cyanosis
Potential Interactions
- ⚡High-frequency ventilation may interfere with distribution
- ⚡Nitric oxide therapy requires careful monitoring of oxygenation
- ⚡Corticosteroids may affect surfactant production timing
- ⚡Inhaled bronchodilators may alter lung mechanics post-treatment
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Comparative effectiveness of synthetic surfactant with SP-B and SP-C peptides in neonatal respiratory distress syndrome
Systematic review comparing synthetic surfactants including lucinactant to animal-derived preparations, showing comparable efficacy in reducing mortality and morbidity in premature infants.
Lucinactant versus poractant alfa in preterm infants with respiratory distress syndrome
Randomized controlled trial demonstrating non-inferiority of lucinactant compared to porcine surfactant for primary treatment of RDS in preterm infants.
KL4-surfactant in respiratory distress syndrome: a randomized controlled trial
Multi-center trial showing reduced mortality and improved respiratory outcomes with lucinactant treatment compared to standard care in very low birth weight infants.
Synthetic lung surfactant with SP-B and SP-C peptide mimics
Preclinical research examining the biophysical properties of KL4 peptide and its ability to restore surface tension reduction in surfactant-deficient conditions.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Lucinactant is completely synthetic, eliminating the risk of viral transmission and providing more consistent composition. The KL4 peptide mimics natural surfactant proteins while avoiding potential immunogenic reactions from animal proteins.
Research shows promise for adult ARDS treatment, but lucinactant is primarily studied and approved for neonatal respiratory distress syndrome. Adult applications remain largely investigational.
Effects typically appear within minutes of intratracheal administration, with improved oxygenation and lung compliance measurable within 1-2 hours of treatment.
Store refrigerated at 2-8°C and use within 2 hours once opened. The suspension should be warmed to body temperature before administration but never heated above 37°C.
Typically 1-3 doses are administered depending on respiratory response. Additional doses may be given every 6 hours if respiratory distress persists and ventilator requirements remain high.
Yes, it must be given through an endotracheal tube using specific positioning and ventilation techniques to ensure even distribution throughout both lungs. Healthcare providers need specialized training.
Continuous monitoring of oxygen saturation, heart rate, blood pressure, and ventilator parameters is essential. Chest X-rays may be needed to assess lung expansion and rule out complications.
No, lucinactant should not be mixed with other drugs or solutions. It should be administered separately through the endotracheal tube as a single agent.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.